# A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

> **NCT04162327** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 55 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IBI315
- **DRUG:** IBI315

## Key facts

- **NCT ID:** NCT04162327
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-26
- **Primary completion:** 2022-01-27
- **Final completion:** 2023-06-20
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162327, "A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04162327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*